Pharmacology & Therapeutics

Article	Citations
Editorial Board	366
Adenosine receptor signalling as a driver of pulmonary fibrosis	332
WITHDRAWN: 17th International conference on bioactive lipids in cancer, inflammation and related diseases virtual special issue	286
Lipid metabolism in AKI and AKI-CKD transition: Dysregulation, lipotoxicity and therapeutic potential	237
The role of macrophages in asthma-related fibrosis and remodelling	237
Collateral lethality: A unique type of synthetic lethality in cancers	219
Retinoid dynamics in vision: from visual cycle biology to retina disease treatments	212
Unlocking the power of affibody conjugated radioactive metallopharmaceuticals for targeted cancer diagnosis and therapy	206
HIV-associated neurotoxicity and cognitive decline: Therapeutic implications	197
Measuring brain docosahexaenoic acid turnover as a marker of metabolic consumption	189
Inflammation, lipids, and pain in vulvar disease	178
Exploiting the obesity-associated immune microenvironment for cancer therapeutics	160
Matrikines in the skin: Origin, effects, and therapeutic potential	148
Treatment strategies for leptomeningeal disease in patients with breast cancer	145
Unfolded protein responses: Dynamic machinery in wound healing	143
Efficacy and safety of immune-modulating therapy for primary sclerosing cholangitis: A systematic review and meta-analysis	141
Potential neonatal toxicity of new psychoactive substances	141
Non-canonical G protein signaling	131
Treatment approaches for alcohol use disorder with metabolic dysfunction	126
New therapeutic horizons for plasma phospholipid transfer protein (PLTP): Targeting endotoxemia, infection and sepsis	122
Endothelial dysfunction as a complication of anti-cancer therapy	119
Sulfoconjugation of protein peptides and glycoproteins in physiology and diseases	117
Management of drug-resistant hypertension as a heterogeneous disorder	117
Myeloid cells in the era of cancer immunotherapy: Top 3 unanswered questions	107
Is the peroxisome proliferator-activated receptor gamma a putative target for epilepsy treatment? Current evidence and future perspectives	105

Pharmacological modulation of respiratory control: Ampakines as a therapeutic strategy	101
Novel approaches to target fibroblast mechanotransduction in fibroproliferative diseases	100
Imaging neuroinflammation with TSPO: A new perspective on the cellular sources and subcellular localization	98
TAAR1 as an emerging target for the treatment of psychiatric disorders	97
Cell-based therapies for vascular regeneration: Past, present and future	95
Recent drug design strategies and identification of key heterocyclic scaffolds for promising anticancer targets	95
Novel strategies and promising opportunities for targeted protein degradation: An innovative therapeutic approach to overcome cancer resistance	95
Harnessing and delivering microbial metabolites as therapeutics via advanced pharmaceutical approaches	95
Regulatory lipid vicinal diols counteract the biological activity of epoxy fatty acids and can act as biomarkers and mechanisms for disease progression	93
The phospholipase A2 superfamily as a central hub of bioactive lipids and beyond	92
Targeting the p38α pathway in chronic inflammatory diseases: Could activation, not inhibition, be the appropriate therapeutic strategy?	91
Contribution of non-selective membrane channels and receptors in epilepsy	90
Boron in cancer therapeutics: An overview	90
Dysregulation of metabolic pathways in pulmonary fibrosis	89
Editorial Board	89
Corrigendum to “The role of CD71+ erythroid cells in the regulation of the immune response” [Pharmacology & Therapeutics 228 (2021) 107927]	84
Review: Sex-related differences in the treatment of cardiac arrhythmia	84
Bispecific antibodies for the treatment of neuroblastoma	81
Wnt signaling: A prospective therapeutic target for chronic pain	80
G protein-coupled receptor-effector macromolecular membrane assemblies (GEMMAs)	78
PGRMC1: An enigmatic heme-binding protein	78
The pathomimetic oAβ25–35 model of Alzheimer's disease: Potential for screening of new therapeutic agents	76
Pharmacological treatment of cardiogenic shock – A state of the art review	74
Emerging role of ferroptosis in breast cancer: New dawn for overcoming tumor progression	74
Editorial Board	73
Recent advances in metabolism and toxicity of tyrosine kinase inhibitors	72
Natural products that alleviate depression: The putative role of autophagy	70
Interactions between NSAIDs, opioids and the gut microbiota - Future perspectives in the management of inflammation and pain	70
Drug-drug interactions that alter the exposure of glucuronidated drugs: Scope, UDP-glucuronosyltransferase (UGT) enzyme selectivity, mechanisms (inhibition and induction), and clinical significance	69
Targeting Sirtuin1 to treat aging-related tissue fibrosis: From prevention to therapy	69
Therapeutic implications of impaired nuclear receptor function and dysregulated metabolism in Wilson's disease	68
DNA methylation in cell plasticity and malignant transformation in liver diseases	67
Targeting mGluR2/3 for treatment of neurodegenerative and neuropsychiatric diseases	66
Air pollution and diseases: signaling, G protein-coupled and Toll like receptors	66
Stabilizing the neural barrier – A novel approach in pain therapy	65
A systematic review on renal effects of SGLT2 inhibitors in rodent models of diabetic nephropathy	64
Entering the TiME machine: How age-related changes in the tumor immune microenvironment impact melanoma progression and therapy response	63
CircRNAs as upstream regulators of miRNA//HMGA2 axis in human cancer	62
The role of microglia heterogeneity in synaptic plasticity and brain disorders: Will sequencing shed light on the discovery of new therapeutic targets?	61
HDL-based therapeutics: A promising frontier in combating viral and bacterial infections	61
The role of drug-metabolizing enzymes in synthetic lethality of cancer	60
Autophagy inhibitors for cancer therapy: Small molecules and nanomedicines	60
Neuromuscular and cardiac organoids and assembloids: Advanced platforms for drug testing	60
Advances in pathogenesis and therapeutic strategies for osteoporosis	60
Editorial: Beyond the opioid crisis: New targets for the management of chronic pain	59
Chemical diversity, traditional uses, and bioactivities of Rosa roxburghii Tratt: A comprehensive review	59
Noncoding RNA circuitry in melanoma onset, plasticity, and therapeutic response	58
Regulation of feeding and therapeutic application of bioactive peptides	58
MAS-related G protein-coupled receptors X (MRGPRX): Orphan GPCRs with potential as targets for future drugs	57
Recent advances in riboflavin transporter RFVT and its genetic disease	56

Optimizing drug therapies in cardiac amyloidosis	56
In vitro functional assays as a tool to study new synthetic opioids at the μ-opioid receptor: Potential, pitfalls and progress	56
Endothelial shear stress signal transduction and atherogenesis: From mechanisms to therapeutics	55
Extracellular vesicles in cardiovascular disease: Biological functions and therapeutic implications	55
Therapeutic targeting of DNA methylation alterations in cancer	55
Myeloperoxidase: Growing importance in cancer pathogenesis and potential drug target	55
17β-hydroxysteroid dehydrogenases in the progression of nonalcoholic fatty liver disease	55
Emerging roles of RNA ac4C modification and NAT10 in mammalian development and human diseases	55
Update on treatment of abdominal pain in irritable bowel syndrome: A narrative review	54
Corrigendum to “Drug discovery through biophysical techniques: Methods and applications” [pharmacology and therapeutics volume 277 (2026) 108947]	54
Pharmacological potential of cyclic nucleotide signaling in immunity	54
The emerging science of Glioception: Contribution of glia in sensing, transduction, circuit integration of interoception	53
Editorial Board	53
Therapeutic exploration of biased ligands at class A G protein-coupled receptors over the past 20 years	53
Hepatic solute carrier transporters and drug therapy: Regulation of expression and impact of genetic variation	53
Consideration of albumin-mediated hepatic uptake for highly protein-bound anionic drugs: Bridging the gap of hepatic uptake clearance between in vitro and in vivo	51
Bridging the gap: The endocannabinoid system as a functional fulcrum for benzodiazepines in a novel frontier of anxiety pharmacotherapy	50
Emerging methods for and novel insights gained by absolute quantification of mitochondrial DNA copy number and its clinical applications	50
MicroRNAs in drug addiction: Current status and future perspectives	49
Translating biased agonists from molecules to medications: Serotonin 5-HT1A receptor functional selectivity for CNS disorders	49
Cannabinoid receptor 1 ligands: Biased signaling mechanisms driving functionally selective drug discovery	49
Pathological changes in GPCR signal organisation: Opportunities for targeted therapies for triple negative breast cancer	48
CDNF and ER stress: Pharmacology and therapeutic possibilities	48
Musculoskeletal crosstalk in chronic obstructive pulmonary disease and comorbidities: Emerging roles and therapeutic potentials	48
Immunotherapy for hepatocellular carcinoma: Recent advances and future targets	47
Organic anion transporters in remote sensing and organ crosstalk	46
Lactate acidosis and simultaneous recruitment of TGF-β leads to alter plasticity of hypoxic cancer cells in tumor microenvironment	46
Cerebrovascular protective functions of amyloid precursor protein: Progress and therapeutic prospects	46
Editorial Board	45
The tissue-specific transcriptional landscape underlines the involvement of endothelial cells in health and disease	45
Integrins in cancer: Emerging mechanisms and therapeutic opportunities	45
Exploring the landscape of post-translational modification in drug discovery	45
Pharmacological interventions for intraplaque neovascularization in atherosclerosis	43
Targeting cancer-associated fibroblasts: Challenges, opportunities and future directions	43
Neurobiological mechanisms of botulinum neurotoxin-induced analgesia for neuropathic pain	43
Deliver the promise: RNAs as a new class of molecular entities for therapy and vaccination	43
G protein-coupled estrogen receptor biased signaling in health and disease	43
Modulation of hyaluronan signaling as a therapeutic target in human disease	43
The role and participation of immune cells in the endometrial tumor microenvironment	43
The (neuro)inflammatory system in anxiety disorders and PTSD: Potential treatment targets	43
Editorial Board	42
Molecular mechanisms of ferroptosis and their involvement in brain diseases	42
Phosphorylation of nuclear receptors: Novelty and therapeutic implications	42
Understanding the molecular bridges between the drugs and immune cell	41
Targeting cell cycle checkpoints for glioma therapy	41
Attributes novel drug candidate: Constitutive GPCR signal bias mediated by purinergic receptors	41
Experimental considerations for the assessment of in vivo and in vitro opioid pharmacology	40
Potential targeting of the tumor microenvironment to improve cancer virotherapy	40
RNA renaissance: Harnessing non-coding RNA therapeutics for hepatocellular carcinoma	40
A map of molecular drug targets and therapeutics for the US FDA-approved drugs: The impact of expedited regulatory pathways and first-in-class drug approvals on drug innovation	40
Following the design path of isoform-selective Hsp90 inhibitors: Small differences, great opportunities	40
Development and clinical translation of P2X7 receptor antagonists: A potential therapeutic target in coronary artery disease?	39
Annexin A1 in neurological disorders: Neuroprotection and glial modulation	39
Advances in anticancer alkaloid-derived metallo-chemotherapeutic agents in the last decade: Mechanism of action and future prospects	39
Platelet lipid metabolism in vascular thrombo-inflammation	39
Prolactin and pain of endometriosis	38
Editorial Board	38
Targeting the Semaphorin3E-plexinD1 complex in allergic asthma	37
From bench to clinic: Emerging therapies for corneal scarring	37
Early life adversities, psychopathologies and novel pharmacological strategies	36
The antidepressant actions of ketamine and its enantiomers	36
Modulating glucocorticoid receptor actions in physiology and pathology: Insights from coregulators	36
Nanotechnology and nano-sized tools: Newer approaches to circumvent oncolytic adenovirus limitations	35
Post-COVID pulmonary sequelae: Mechanisms and potential targets to reduce persistent fibrosis	35
Immune cells and their derived microRNA-enriched extracellular vesicles in nonalcoholic fatty liver diseases: Novel therapeutic targets	35
The essential role of docosahexaenoic acid and its derivatives for retinal integrity	35
Plant-derived nanovesicles and therapeutic application	34
Targeting myeloid-derived suppressor cells to enhance natural killer cell-based immunotherapy	34
Editorial Board	34
Signaling pathways in brain ischemia: Mechanisms and therapeutic implications	34
Roles of NLRC4 inflammasome in neurological disorders: Mechanisms, implications, and therapeutic potential	34
Editorial Board	34
Therapeutic antibodies – natural and pathological barriers and strategies to overcome them	34
Endotheliopathy in the metabolic syndrome: Mechanisms and clinical implications	33
Gene and stem cell therapy for inherited cardiac arrhythmias	33
Chloride channels in the lung: Challenges and perspectives for viral infections, pulmonary arterial hypertension, and cystic fibrosis	33
Anti-cancer activity of sustained release capsaicin formulations	33
Biased signaling in drug discovery and precision medicine	33
Post-translational modifications of histone and non-histone proteins in epigenetic regulation and translational applications in alcohol-associated liver disease: Challenges and research opportunities	33
Protoporphyrin IX-induced phototoxicity: Mechanisms and therapeutics	33

Distinct mechanisms underlying therapeutic potentials of CD20 in neurological and neuromuscular disease	33
Gut dysbiosis, defective autophagy and altered immune responses in neurodegenerative diseases: Tales of a vicious cycle	32
Bile acids and neurological disease	32
Multitasking bamboo leaf-derived compounds in prevention of infectious, inflammatory, atherosclerotic, metabolic, and neuropsychiatric diseases	32
Amino acid transporter LAT1 (SLC7A5) as a molecular target for cancer diagnosis and therapeutics	32
Treatment of overdose in the synthetic opioid era	32
Current state and novel outlook on prevention and treatment of rising antibiotic resistance in urinary tract infections	32
Lessons learned from 20 years of preclinical testing in pediatric cancers	32
Icosapent ethyl in cardiovascular prevention: Resolution of inflammation through the eicosapentaenoic acid - resolvin E1 - ChemR23 axis	32
GLP-1 receptor agonists, are we witnessing the emergence of a paradigm shift for neuro-cardio-metabolic disorders?	32
Retina-directed gene therapy: Achievements and remaining challenges	32
Editorial Board	32